Nektar Therapeutics (NASDAQ: NKTR) reported Q3 EPS of $0.39, $0.22 better than the analyst estimate of $0.17. Revenue for the quarter came in at $152.9 million versus the consensus estimate of $114.62 million.

For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.